Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCSW) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for HeartSciences (HSCSW) over the last 4 years, with Q4 2025 value amounting to $777192.0.

  • HeartSciences' Gains from Investment Securities rose 101527.71% to $777192.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $777192.0, marking a year-over-year increase of 21564.69%. This contributed to the annual value of $173659.0 for FY2025, which is 83069.83% up from last year.
  • Latest data reveals that HeartSciences reported Gains from Investment Securities of $777192.0 as of Q4 2025, which was up 101527.71% from $777400.0 recorded in Q3 2025.
  • HeartSciences' Gains from Investment Securities' 5-year high stood at $777400.0 during Q3 2025, with a 5-year trough of $38796.0 in Q3 2022.
  • For the 4-year period, HeartSciences' Gains from Investment Securities averaged around $238584.2, with its median value being $86802.0 (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 8049.41% in 2023, then skyrocketed by 139319.09% in 2025.
  • Quarter analysis of 4 years shows HeartSciences' Gains from Investment Securities stood at $510431.0 in 2022, then crashed by 80.49% to $99564.0 in 2023, then plummeted by 30.01% to $69686.0 in 2024, then soared by 1015.28% to $777192.0 in 2025.
  • Its Gains from Investment Securities was $777192.0 in Q4 2025, compared to $777400.0 in Q3 2025 and $173659.0 in Q2 2025.